Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Han KA, Chon S, Chung CH, Lim S, Lee KW, Baik S, Jung CH, Kim DS, Park KS, Yoon KH, Lee IK, Cha BS, Sakatani T, Park S, Lee MK. Han KA, et al. Among authors: sakatani t. Diabetes Obes Metab. 2018 Oct;20(10):2408-2415. doi: 10.1111/dom.13394. Epub 2018 Jul 16. Diabetes Obes Metab. 2018. PMID: 29862619 Free PMC article. Clinical Trial.
Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Kashiwagi A, Sakatani T, Nakamura I, Akiyama N, Kazuta K, Ueyama E, Takahashi H, Kosakai Y. Kashiwagi A, et al. Among authors: sakatani t. Endocr J. 2018 Jul 28;65(7):693-705. doi: 10.1507/endocrj.EJ17-0491. Epub 2018 May 29. Endocr J. 2018. PMID: 29848902 Free article. Clinical Trial.
Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study.
Ishihara H, Yamaguchi S, Nakao I, Asahina S, Sakatani T. Ishihara H, et al. Among authors: sakatani t. Diabetol Int. 2018 Jul 16;10(1):37-50. doi: 10.1007/s13340-018-0359-x. eCollection 2019 Jan. Diabetol Int. 2018. PMID: 30800562 Free PMC article.
The Effects of Peroxisome Proliferator-Activated Receptor-Delta Modulator ASP1128 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.
van Till JWO, Nojima H, Kameoka C, Hayashi C, Sakatani T, Washburn TB, Molitoris BA, Shaw AD, Engelman DT, Kellum JA. van Till JWO, et al. Among authors: sakatani t. Kidney Int Rep. 2023 Apr 8;8(7):1407-1416. doi: 10.1016/j.ekir.2023.04.004. eCollection 2023 Jul. Kidney Int Rep. 2023. PMID: 37441472 Free PMC article.
Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.
Ando F, Kashiwada T, Kuroda S, Fujii T, Takano R, Miyabe Y, Kunugi S, Sakatani T, Miyanaga A, Asatsuma-Okumura T, Hashiguchi M, Kanazawa Y, Ohashi R, Yoshida H, Seike M, Gemma A, Iwai Y. Ando F, et al. Among authors: sakatani t. Front Pharmacol. 2024 May 7;15:1384731. doi: 10.3389/fphar.2024.1384731. eCollection 2024. Front Pharmacol. 2024. PMID: 38774209 Free PMC article.
189 results